Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compound Edaravone Injection for Acute Ischemic Stroke
NCT01929096Phase 2Completed
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Aug 2013
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of edaravone dexborneol in ischemic stroke (4 arms), sponsored by Simcere Pharmaceutical Group. Primary endpoints: modified Rankin Scale at day 90 and National Institutes of Health Stroke Scale at day 14. Started Aug 2013; status: completed.
02
Drugs
edaravone dexborneol
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT01929096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01929096.